Keros Therapeutics Inc (NASDAQ:KROS) currently has a daily average trading volume of 389.93K but it saw 14609366 shares traded in last market. With a market cap of 746.55M USD, the company’s current market price of $18.43 came falling about -73.15 while comparing to the previous closing price of $68.65. In past 52 weeks, the stock remained buoying in the range of price level as high as $73.00 and as low as $27.31. In the recent trading on the day, stock has struck highest price mark of $15.67 while lowest mark touched by it was $19.32.
Taking a look at 20-day trading activity of Keros Therapeutics Inc (KROS) gives us an average price of $58.03, while its current price level is -74.75% below from 52-week high level whereas it is -32.52% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $59.98 while that of 200 days or SMA-200 reads an average of $55.36. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.71% during that period while stretching the period over a month that decreases to 6.81%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 22.26 which implies that the stock is in oversold territory.
Over the week, KROS’s stock price is moving -71.48% down while it is -71.59% when we observe its performance for the past one month. Year-to-date it is -53.65% down and over the past year, the stock is showing a downside performance of -37.86%.
The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -0.89 while estimate for next year EPS is -4.68. In next quarter, company is expected to be making quarterly sales of $4.39M as analysts are expecting the sales for current fiscal year at $29.05M and seeing the company making $33.43M in sales next year. Moreover, analysts are in estimates of $33.38M for current-quarter revenue.
Currently, Keros Therapeutics Inc’s total number of outstanding shares is 39.26M with 5.43% of that held by the insiders while 100.93% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -33.00% and return on equity (ROE) at -43.82%. Stock’s beta reads 1.20. Stock has a price to book (P/B) ratio of 1.36 while price to sale or P/S ratio amounts to 1148.54. Its return on asset (ROA) is -40.10% on average.
